Eir Ventures Invests in Purpose Pharma
Purpose Pharma is a patient-centric European based pharmaceutical company focusing on the development and commercialization of novel rare disease and specialty care products in areas of high unmet medical need.
jamiehan
Hoba Therapeutics raises EUR 23 million
Hoba Therapeutics, a Novo Holdings founded Danish biotech company dedicated to developing novel therapeutic proteins for patients living with chronic neuropathic pain and hearing loss, today announced that it has raised EUR 23 million (USD 25 million) in a Series A financing first close.
Eir Ventures invests in Dania Tx
Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx). The company is based on research from renowned professor Kristian Helin and dr. Karl Agger originating from Helin’s former research group at the University of Copenhagen. The ambition is to develop a treatment for acute myeloid leukaemia, which also holds potential for treatment of other types of cancer.
Eir Ventures celebrates 3 years anniversary
On July 10, 2020, Eir Ventures I was launched with the announcement of the first close of our fund. Since the launch, Eir Ventures have completed investments in 17 pioneering life science companies; 5 companies have taken their development programs into clinical testing, and two companies have been listed on NASDAQ (US). We continue to develop the portfolio and look forward to the coming years in the fund. The Eir Ventures team sends the best wishes for the summer to all our colleagues and friends in the Nordic and International Life Science community.
Lovisa Backemar new Principal
Eir Ventures welcomes Lovisa Backemar as Principal in the Eir Ventures Team. Lovisa is a Medical Doctor and holds a PhD in clinical epidemiology from the Karolinska Institute. Prior to joining Eir Ventures, Lovisa served as Head of Business Development at the Swedish healthcare provider Capio, where she played a key role in setting the strategic direction and leading growth projects. Lovisa also gained valuable experience as a management consultant at Boston Consulting Group, working on diverse projects in different industries, mainly MedTech and Pharma. Lovisa will be based in Stockholm.
Eir invests in RAPP
Eir Ventures are delighted to announce our most recent investment in RAPP.
The company was founded in Sweden based on Professor Ulrica Nilsson’s research, offering an evidence-based, interactive, and patient-centric digital platform that addresses several needs in the field of Postoperative Care and Recovery. Rapp aims to implement value-based care by focusing on improving quality of care and overall patient satisfaction after “day surgery” (outpatient surgery) through its well-established monitoring system, while in the meantime enabling the healthcare system to improve an efficient workflow and cut healthcare costs accordingly. Considering trends of increasing number of surgical procedures carried out on a same-day basis in recent years, medical value generated with this digital platform will benefit healthcare systems, patients as well as research community to further improve the processes.
Eir invests in GutCRINE
Eir Ventures are delighted to announce our most recent investment in GutCRINE. The company is a pioneering spin out from Copenhagen University developing a new first in class therapy targeting metabolic and age-related diseases like obesity, type 2 diabetes, osteoporosis and Parkinson’s disease.
Eir Ventures leads €28M investment in Scenic Biotec
Scenic Biotech is a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders
Eir Ventures invests in Henlez
Henlez mission is to transform the management of skin conditions by using enzymes.
Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin. The company was founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen.
Eir Ventures portfolio company, Pretzel Therapeutics, announces USD 72,5m series A financing
Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. The name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.